CCL21 and non-small cell lung carcinoma: A preclinical proof of concept study that led to the CCL21-DC phase 1 clinical trial mentioned previously utilized DCs transduced with an adenovirus expressing CCL21 (DC-AdCCL21) to intratumorally vaccinate mice bearing NSCLC tumors [159].